Advanced search
Add to list

Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984)

(2006) EUROPEAN JOURNAL OF CANCER. 42(10). p.1399-1406
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
BIESMA, B., et al. “Docetaxel and Cisplatin as Induction Chemotherapy in Patients with Pathologically-Proven Stage IIIA N2 Non-Small Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer (EORTC 08984).” EUROPEAN JOURNAL OF CANCER, vol. 42, no. 10, ELSEVIER SCI LTD, 2006, pp. 1399–406.
APA
BIESMA, B., MANEGOLD, C., SMIT, H., WILLEMS, L., LEGRAND, C., PASSIOUKOV, A., … GIACCONE, G. (2006). Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). EUROPEAN JOURNAL OF CANCER, 42(10), 1399–1406.
Chicago author-date
BIESMA, B, C MANEGOLD, HJM SMIT, L WILLEMS, C LEGRAND, A PASSIOUKOV, Jan Van Meerbeeck, and G GIACCONE. 2006. “Docetaxel and Cisplatin as Induction Chemotherapy in Patients with Pathologically-Proven Stage IIIA N2 Non-Small Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer (EORTC 08984).” EUROPEAN JOURNAL OF CANCER 42 (10): 1399–1406.
Chicago author-date (all authors)
BIESMA, B, C MANEGOLD, HJM SMIT, L WILLEMS, C LEGRAND, A PASSIOUKOV, Jan Van Meerbeeck, and G GIACCONE. 2006. “Docetaxel and Cisplatin as Induction Chemotherapy in Patients with Pathologically-Proven Stage IIIA N2 Non-Small Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer (EORTC 08984).” EUROPEAN JOURNAL OF CANCER 42 (10): 1399–1406.
Vancouver
1.
BIESMA B, MANEGOLD C, SMIT H, WILLEMS L, LEGRAND C, PASSIOUKOV A, et al. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). EUROPEAN JOURNAL OF CANCER. 2006;42(10):1399–406.
IEEE
[1]
B. BIESMA et al., “Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984),” EUROPEAN JOURNAL OF CANCER, vol. 42, no. 10, pp. 1399–1406, 2006.
@article{360607,
  author       = {{BIESMA, B and MANEGOLD, C and SMIT, HJM and WILLEMS, L and LEGRAND, C and PASSIOUKOV, A and Van Meerbeeck, Jan and GIACCONE, G}},
  issn         = {{0959-8049}},
  journal      = {{EUROPEAN JOURNAL OF CANCER}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{1399--1406}},
  publisher    = {{ELSEVIER SCI LTD}},
  title        = {{Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984)}},
  volume       = {{42}},
  year         = {{2006}},
}

Web of Science
Times cited: